Abstract
Inversions are known contributors to the pathogenesis of genetic diseases. Identifying inversions poses significant challenges, making it one of the most demanding structural variants (SVs) to detect and interpret. Recent advancements in sequencing technologies and the development of publicly available SV datasets have substantially enhanced our capability to explore inversions. However, a cross-comparison in those datasets remains unexplored. In this study, we reported a proband with familial hemophagocytic lymphohistiocytosis type-3 carrying c.1389+1G>A in trans with NC_000017.11:75576992_75829587inv disrupting UNC13D, an inversion present in 0.006345% of individuals in gnomAD(v4.0). Based on this result, we investigate the features of potentially pathogenic inversions in public datasets. 98.9% of inversions are rare in gnomAD, and they disrupt 5% of protein-coding genes associated with a phenotype in OMIM. We then conducted a comparative analysis of the datasets, including gnomAD, DGV, and 1KGP, and two recent studies from the Human Genome Structural Variation Consortium revealed common and dataset-specific inversion characteristics suggesting methodology detection biases. Next, we investigated the genetic features of inversions disrupting the protein-coding genes by classifying the intersections between them into three categories. We found that most of the protein-coding genes in OMIM disrupted by inversions are associated with autosomal recessive phenotypes regardless of categories supporting the hypothesis that inversions in trans with other variants are hidden causes of monogenic diseases. This effort aims to fill the gap in our understanding of the molecular characteristics of inversions with low frequency in the population and highlight the importance of identifying them in rare disease studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the United States National Institute of General Medical Sciences NIGMS R01 GM132589.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is approved by the Baylor College of Medicine (BCM) Institutional Review Board and WIRB for the Pacific Northwest Research Institute (IRB Protocol #H-47127/20202158).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
